Alejandro Toro-Pedroza

Dr. Alejandro Toro-Pedroza

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JBJuan Camilo Baena
Juan Camilo Baena
LLLucy Perez Lugo
Lucy Perez Lugo
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
TKToshio Kitawaki
Toshio Kitawaki
ALAlexandre Roumenov Loukanov
Alexandre Roumenov Loukanov
Cancer treatment has traditionally focused on eliminating tumor cells but faces challenges such as resistance and toxicity. A promising direction involves targeting the tumor microenvironment using CAR T cell immunotherapy, which has shown potential for treating relapsed and refractory cancers but is limited by high costs, resistance, and toxicity, especially in solid tumors. The integration of nanotechnology into ICAM cell therapy, a concept we have named “CAR T nanosymbiosis”, offers new opportunities to overcome these challenges. Nanomaterials can enhance CAR T cell delivery, manufacturing, activity modulation, and targeting of the tumor microenvironment, providing better control and precision. This approach aims to improve the efficacy of CAR T cells against solid tumors, reduce associated toxicities, and ultimately enhance patient outcomes. Several studies have shown promising results, and developing this therapy further is essential for increasing its accessibility and effectiveness. Our “addition by subtraction model” synthesizes these multifaceted elements into a unified strategy to advance cancer treatment paradigms.

11 February 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JBJuan Camilo Baena-Valencia
Juan Camilo Baena-Valencia
SCSergio Camilo Cabrera-Salcedo
Sergio Camilo Cabrera-Salcedo
YSYesenia Carrera Suárez
Yesenia Carrera Suárez
JBJuan M. Biancha-Vasco
Juan M. Biancha-Vasco
LRLady J. Rios-Serna
Lady J. Rios-Serna
ALAlexandre Roumenov Loukanov
Alexandre Roumenov Loukanov
Exosomes are nanoscale extracellular vesicles that transfer proteins, nucleic acids, and lipids, reflecting the state of their parent cells. A persistent scientific challenge is that tumor-derived exosomes (TDEs) facilitate immune evasion, remodel the tumor microenvironment, and create premetastatic niches, intensifying tumor aggressiveness and undermining therapeutic efficacy, ultimately narrowing treatment options to palliative strategies in advanced settings. Yet their dual roles as suppressive agents and potential therapeutic tools remain poorly integrated within current cancer immunotherapy frameworks. This review examines the molecular mechanisms underlying TDE-mediated immune suppression and therapeutic resistance, while also highlighting engineering strategies to exploit or counteract exosome biology. Exosomes derived from chimeric antigen receptor (CAR) T cells preserve antigen specificity and cytotoxic components without the risks of uncontrolled proliferation or cytokine release, offering a safer class of cell free immunotherapies. Advances in genetic engineering, hybrid vesicle design, and nanotechnology have extended exosome applications to the delivery of CRISPR/Cas systems, chemotherapeutic agents, immunoregulatory RNAs, and vaccines, with liposome or nanoparticle integration enhancing targeting and efficacy. Remaining obstacles include the lack of standardized protocols, scalability issues in production, and unresolved regulatory frameworks. Drawing on The Art of War, exosomes can be envisioned as avatars of strategy, discreet messengers capable of undermining host defenses while simultaneously carrying the potential to redirect immunity against the tumor. By embodying both deception and counterattack, they illustrate the capacity to penetrate hidden barriers and redefine the therapeutic battlefield, opening new horizons for precision cancer immunotherapy. Graphical abstract

21 November 2025 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
JVJuan Sebastián Victoria
Juan Sebastián Victoria
MCMiguel Cardona-Sepúlveda
Miguel Cardona-Sepúlveda
Juan Esteban Garcia-RobledoJuan Esteban Garcia-Robledo
Juan Esteban Garcia-Robledo
LRLady J. Rios-Serna
Lady J. Rios-Serna
JBJuan C. Baena
Juan C. Baena

27 August 2025 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
OMOscar Felipe Borja Montes
Oscar Felipe Borja Montes
DHDarrell Horton
Darrell Horton
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
TETomas Escobar-Gil
Tomas Escobar-Gil
DBDaniel Babu
Daniel Babu
AEAla Ebaid
Ala Ebaid
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially. We present a rare case of this phenomenon in a 79-year-old male patient. Case description: A 79-year-old male with refractory B-ALL underwent a lineage switch to acute myeloid leukaemia following treatment with blinatumomab and InO. The patient initially achieved remission after initial therapy but relapsed and was subsequently treated with blinatumomab. Due to adverse effects, the treatment was discontinued. He was then treated with InO but again relapsed. A subsequent bone marrow biopsy revealed morphologic evidence of residual B-ALL, but with the presence of acute monocytic leukaemia. Fluorescence in situ hybridisation (FISH) analysis demonstrated an additional copy of KMT2A in a large percentage of cells which was a feature present since the initial diagnosis. Unfortunately, the patient’s condition deteriorated, and he died. Conclusion: This case underscores potential complication of lineage switch following treatment with B-cell directed therapies. Although such therapies have improved outcomes in B-cell malignancies, clinicians should remain aware of rare risks such as lineage transformation. Timely recognition is essential to guide appropriate clinical management.

14 January 2026 in Global Heart
Verified
Journal Article
Open access
JLJuan David Lopez
Juan David Lopez
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
JAJuan Pablo Arango-Ibanez
Juan Pablo Arango-Ibanez
VAValeria Azcarate-Rodriguez
Valeria Azcarate-Rodriguez
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background: Heart transplantation (HT) remains the definitive treatment for advanced heart failure that is refractory to both medical and invasive therapies. Although global registries offer extensive data on survival outcomes, there is a relative paucity of information regarding HT outcomes in Latin America (LATAM), particularly in Colombia. Methods: This study analyzed adult patients who underwent HT between 1995 and 2024, using data obtained from an institutional HT registry (RETRAC) in Cali, Colombia. Survival outcomes were evaluated using Kaplan–Meier curves and Cox proportional hazards models. Results: We included 260 patients who underwent HT in this 29-year cohort from a LATAM country. The median age at transplantation was 51 years, and 77.7% were male. The primary etiologies were idiopathic/dilated cardiomyopathy (IDC) (41.3%), ischemic cardiomyopathy (IC) (27.0%), and valvular heart disease (VHC) (9.7%). The most prevalent comorbidities were hypertension (HTN) (48.3%), diabetes mellitus (DM) (18.9%), and chronic kidney disease (CKD) (13.1%). The overall median survival following HT was 7.4 years. One-year survival was 74.6% (n = 194), five-year survival was 56.9% (n = 147), and ten-year survival was 46.9% (n = 122). Survival differed significantly by age and sex, with patients aged <40 years demonstrating the highest median survival (8.4 years) and those aged ≥60 years the lowest (2.2 years) (p = 0.038). The 40- to 49-year age group exhibited the most pronounced reduction in survival; however, this effect was attenuated after adjustment. Among patients under 40 years, females had significantly higher mortality compared to males (p = 0.0078), with younger males exhibiting better survival. Additionally, patients transplanted between 2016 and 2020 had higher survival rates. CKD was identified as a significant independent risk factor for increased mortality (hazard ratio (HR) = 1.79; 95% CI: 1.15–2.79; p = 0.01). Conclusions: HT patients in Colombia exhibit demographic and clinical profiles comparable to global cohorts; however, they demonstrate lower survival rates and poorer clinical outcomes compared to international registries, such as the International Society for Heart and Lung Transplantation registry. Nonetheless, clinical outcomes are more favorable than those reported in other studies from the LATAM region. CKD emerged as a significant independent predictor of mortality. These findings highlight the need for region-specific strategies aimed at improving HT outcomes in LATAM.

9 January 2025
Verified
Book Chapter
Open access
PDF file
FJFrancisco Jaramillo
Francisco Jaramillo
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
PCPedro Caraballo
Pedro Caraballo
ÁMÁlvaro Mondragón
Álvaro Mondragón
MMMildrey Mosquera-Escudero
Mildrey Mosquera-Escudero
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for treating high-risk acute leukemias in developing countries but is costly and complex. Our cost-effective protocol achieves promising results, with 12-month disease-free survival rates of 52% for acute lymphoblastic leukemia and 65% for acute myeloid leukemia, close to those reported by JACIE-accredited units. Despite the lower transplant rates and limited access compared to developed nations, advancements in donor selection, monitoring, and infection prophylaxis have improved outcomes. Continued research and cost-effective strategies are essential to enhance accessibility and success rates in emerging economies.